title: A high dose chemoradiotherapy and peripheral blood stem cell support combined with the CD34(+)-selection method in cyclin D1(+)-mantle cell lymphoma.
abstract: Mantle cell lymphoma (MCL) is currently regarded as one of the most incurable lymphomas, although reliable prognostic indicators are not yet to be defined. In a previous report, it was indicated that most of the patients with immunohistochemically cyclin D1(+)-MCL pursued the lethal clinical course within 7 years, not having achieved complete remission (CR). Recently, a high dose chemoradiotherapy was carried out, this was supported by peripheral blood stem cell transplantation (PBSCT) using the CD34(+)-selection method in a 48-year-old female patient with cyclin D1(+)-MCL. The tumor cells were detected in her peripheral blood despite four courses of combination chemotherapy using CHOP regimen. Soon after the pre-conditioning of total body irradiation (TBI) and high dose melphalan, she received the PBSCT of 1.8 x 10(6)/kg CD34+ cells and showed rapid hematological recovery without life-threatening complications. The patient achieved CR and was alive, without disease, 730 days after PBSCT. Thus, CD34+ selected PBSCT appears to provide further insight into the effective treatment and possible cure of this aggressive disease, i.e. cyclin D1(+)-MCL.
authors.affiliation: Department of Hematology and Chemotherapy, Aichi Cancer Center Hospital, Nagoya, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Uehira
authors.forename: Y
authors.initials: Y
authors.lastname: Kagami
authors.forename: M
authors.initials: M
authors.lastname: Ogura
authors.forename: R
authors.initials: R
authors.lastname: Suzuki
authors.forename: K
authors.initials: K
authors.lastname: Miura
authors.forename: H
authors.initials: H
authors.lastname: Tachi
authors.forename: T
authors.initials: T
authors.lastname: Kurokawa
authors.forename: T
authors.initials: T
authors.lastname: Kinoshita
authors.forename: T
authors.initials: T
authors.lastname: Murate
authors.forename: S
authors.initials: S
authors.lastname: Nakamura
authors.forename: Y
authors.initials: Y
authors.lastname: Morishima
mesh_terms: D018952:Antigens, CD34 / Q000032:analysis; D003131:Combined Modality Therapy; D019938:Cyclin D1 / Q000032:analysis; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods; D006412:Hematopoietic Stem Cells / Q000276:immunology*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000737:chemistry* / Q000532:radiotherapy / Q000628:therapy*; D008558:Melphalan / Q000008:administration & dosage* / Q000627:therapeutic use*; D008875:Middle Aged
chemical_list: D018952:Antigens, CD34; D019938:Cyclin D1; D016179:Granulocyte Colony-Stimulating Factor; D008558:Melphalan